---
schema_version: "secwatch.filing_event.v1"
accession: "0000784199-25-000012"
form_type: "8-K"
ticker: "AORT"
cik: "0000784199"
company_name: "ARTIVION, INC."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T06:37:14.063434+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Artivion Q4 revenue $97.3M (+4% YoY); FY2025 revenue guidance $420-435M

## Summary
- Q4 revenue $97.3M (+4% GAAP, +3% constant currency); On-X, stent grafts, BioGlue each grew 8-10%.
- Q4 net loss $(16.5)M ($0.39/share) vs loss $(4.0)M prior year; Adjusted EBITDA $17.6M (+15%).
- FY2024 revenue $388.5M (+10% GAAP), net loss $(13.4)M vs $(30.7)M in 2023; Adjusted EBITDA $71.3M (+32%).
- FDA granted Humanitarian Device Exemption for AMDS; second PMA module submitted; clinical data showed 50% mortality reduction.
- FY2025 revenue guidance $420-435M (10-14% constant currency growth); adjusted EBITDA $84-91M (18-28% growth).

## SEC filing metadata
- accession: 0000784199-25-000012
- form_type: 8-K
- ticker: AORT
- cik: 0000784199
- company_name: ARTIVION, INC.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/784199/000078419925000012/0000784199-25-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/784199/000078419925000012/aort-20250224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000784199-25-000012
- JSON: https://secwatch.observer/filing/0000784199-25-000012.json
- Plain text: https://secwatch.observer/filing/0000784199-25-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.